SCHEMBL13802494

SCHEMBL13802494

CCOc1cccc(-c2ccccc2CC(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 3/20 0.57
PTGER4 P35408 3/20 0.57
PTGER3 P43115 3/20 0.57
PTGER2 P43116 3/20 0.57
RXRA P19793 1/20 0.55
RXRB P28702 1/20 0.55
CFD P00746 1/20 0.52
PTGS2 P35354 2/20 0.50
ENPP2 Q13822 1/20 0.50
FFAR1 O14842 3/20 0.48
FFAR4 Q5NUL3 2/20 0.48
FABP4 P15090 4/20 0.46
FABP5 Q01469 2/20 0.46
FABP3 P05413 1/20 0.46
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ICMT O60725 2/20 0.46
SLC13A5 Q86YT5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5698013 0.80 RXRA (0.55) RXRARXRBPTGS2FABP4FABP5
SCHEMBL17796988 0.80 RXRA (0.61) RXRARXRBPTGS2FFAR1LMNA
SCHEMBL4089863 0.79 PTGER4 (0.59) PTGER1PTGER4PTGER3PTGER2CFD
SCHEMBL4214472 0.78 RXRA (0.62) RXRARXRBCFDENPP2FFAR1
SCHEMBL9890647 0.78 PTGER1 (0.57) PTGER1PTGER4PTGER3PTGER2PTGS2
SCHEMBL4212932 0.77 RXRA (0.69) PTGER2RXRARXRBFFAR1LMNA
SCHEMBL17797039 0.77 ALDH1A1 (0.60) RXRARXRBPTGS2LMNAMAPK1
Ethane SCHEMBL28588588 0.77 PTGS1 (0.57) PTGER1PTGER4PTGER3PTGER2PTGS2
SCHEMBL538512 0.77 KMT2A (0.60) PTGER1PTGER4PTGER3PTGER2PTGS2
SCHEMBL11017769 0.76 RXRA (0.51) RXRARXRBPTGS2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 PTGER1 1195/4885PTGER4 1561/4885PTGER3 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.